Category: Disclosures

[Disclosure] Celltrion (068270) – Application for Phase 3 Clinical Trial Plan for CT-P13 SC (Zymfentra) in the U.S. (Rheumatoid Arthritis) / 2024-06-19

June 19, 2024August 6, 2026 K-STOCK Editor

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion announced that it has submitted an application for a global Phase 3 clinical trial plan to the U.S. Food and Drug Administration (FDA) to evaluate the efficacy and safety of CT-P13 SC (Zymfentra) in patients with rheumatoid arthritis. 📊 [Key Disclosure Details & Financial Highlights]…

Disclosures, Bio & Healthcare

[Disclosure] Hanwha Ocean (042660) – Other Information / 2024-06-19

June 19, 2024August 9, 2026 K-STOCK Editor

Fact Source: Financial Supervisory Service DART / KOSCOM 💡 3-Second Summary This filing provides notice that the lock-up period for 5,144,087 common shares of Hanwha Ocean held by the Export-Import Bank of Korea expires on June 21, 2024, with the lock-up release date set for June 22, 2024. 📊 [Key Disclosure Highlights & Summary] [Other…

Disclosures, Shipbuilding

[Disclosure] Hana Micron (067310) – Determination of 1st Preliminary Issue Price for Capital Increase / 2024-06-18

June 18, 2024August 2, 2026 K-STOCK Editor

Fact Source: Financial Supervisory Service DART 💡 Executive Summary The 1st preliminary issue price for Hana Micron’s rights offering (5,000,000 common shares) has been determined at KRW 18,520 per share. 📊 Key Disclosure Content & Financial Figures Summary 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of 1st Preliminary Issue Price and Upcoming Final Price…

Semiconductors, Disclosures

[Disclosure] Hana Micron (067310) – (Correction) Decision on Capital Increase with and without Consideration / 2024-06-18

June 18, 2024August 2, 2026 K-STOCK Editor

Fact Source: Financial Supervisory Service DART 💡 Executive Summary Hana Micron disclosed a corrected report regarding its capital increase, updating the preliminary issue price to KRW 18,520 following the confirmation of the 1st preliminary issue price and adjusting the allocation for debt repayment funds while removing the allocation for operating funds. 📊 Key Disclosure Content…

Semiconductors, Disclosures

[Disclosure] Hana Micron (067310) – Ex-Rights (Capital Increase) / 2024-06-18

June 18, 2024August 2, 2026 K-STOCK Editor

Fact Source: Financial Supervisory Service DART 💡 Executive Summary Pursuant to Hana Micron’s rights offering, the ex-rights date takes effect on June 19, 2024, with the ex-rights reference price set at KRW 22,950. 📊 Key Disclosure Content & Financial Figures Summary 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of Ex-Rights Execution and Reference Price…

Semiconductors, Disclosures

[Disclosure] Hanwha Systems (272210) – Sales/Supply Contract / 2024-06-18

June 18, 2024August 11, 2026 K-STOCK Editor

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Hanwha Systems has signed a contract worth approximately KRW 142.1B with the Defense Acquisition Program Administration for the 2024 Tactical Information Communication Network (TICN) Performance-Based Logistics (PBL) project. 📊 [Key Disclosure Details & Financial Metrics] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Contract Performance Progress and…

Disclosures, Defense

[Disclosure] Celltrion (068270) – Approval of Phase 3 Clinical Trial Plan (Part 1) in Europe for CT-P13 SC (Pediatric Ulcerative Colitis) / 2024-06-18

June 18, 2024August 6, 2026 K-STOCK Editor

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion announced that the European Medicines Agency (EMA) has approved Part 1 (trial design and methodology) of its global Phase 3 clinical trial plan for CT-P13 SC (Remsima SC) in pediatric patients with ulcerative colitis. 📊 [Key Disclosure Details & Financial Highlights] 📝 Editor’s Comment (Key…

Disclosures, Bio & Healthcare

[Disclosure] Celltrion (068270) – Approval of Phase 3 Clinical Trial Plan (Part 1) in Europe for CT-P13 SC (Pediatric Crohn’s Disease) / 2024-06-18

June 18, 2024August 6, 2026 K-STOCK Editor

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion announced that the European Medicines Agency (EMA) has approved Part 1 (trial design and methodology) of its global Phase 3 clinical trial plan for CT-P13 SC (Remsima SC) in pediatric patients with Crohn’s disease. 📊 [Key Disclosure Details & Financial Highlights] 📝 Editor’s Comment (Key…

Disclosures, Bio & Healthcare

[Disclosure] Samsung Biologics (207940) – Execution of Material Sales/Supply Contract (Correction) / 2024-06-18

June 18, 2024August 7, 2026 K-STOCK Editor

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics announced a disclosure correction regarding a 2017 contract manufacturing agreement, significantly increasing the contract value from ~KRW 16.8B to ~KRW 250.9B while fully disclosing the counterparty (Baxter Healthcare Corporation) and the contract end date (December 31, 2034). 📊 [Key Disclosure Details & Summary Statistics]…

Disclosures, Bio & Healthcare

[Disclosure] Hanwha Ocean (042660) – Sales and Supply Contract (Correction) / 2024-06-18

June 18, 2024August 9, 2026 K-STOCK Editor

Fact Source: Financial Supervisory Service DART / KOSCOM 💡 3-Second Summary This filing discloses an amendment to Hanwha Ocean’s contract to construct six ultra-large container vessels for an African shipowner, extending the contract completion date from June 30, 2024, to November 25, 2024. 📊 [Key Disclosure Highlights & Summary] [Detailed Terms of Contract] 📝 Editor’s…

Disclosures, Shipbuilding